Rapid Micro Biosystems reported second-quarter revenue of $8.1 million, up 11% from a year earlier, driven by record consumable sales and higher service activity. Gross margin improved to 15% from 4%, while service margin reached a record 49%. The company reaffirmed its full-year 2026 revenue outlook of $37 million to $41 million and raised its annual system-validation target to at least 27. Management expects fourth-quarter gross margin in the mid- to high-20% range and announced an efficiency program that should reduce cash usage by about $1 million for the rest of 2026 and $3 million annually from 2027, targeting positive cash flow by the end of 2028.
Rapid Micro Biosystems IncQ2 revenue up 11%, improved margins, raised validation target, and efficiency program targeting positive cash flow.